GlassScriptPhysician profile
Heather B Allred
NPI 1104859149
$3,957.63
in general payments reported to CMS, 2019-2025
25 companies · $607 in 2025
The $607 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $958 · 2023: $553 · 2024: $1,353 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577 · Consulting Fee: $788 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.18 |
| Consulting Fee | $787.50 |
| Education | $147.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,345.32 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $443.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $410.68 | 2021-2025 | Libtayo, Dupixent |
| Abbvie INC. | $311.37 | 2021-2025 | |
| Revance Therapeutics, INC. | $268.65 | 2024 | Daxxify |
| Janssen Biotech, INC. | $209.64 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $185.00 | 2023-2024 | Bimzelx, Cimzia |
| Genzyme Corporation | $100.25 | 2022-2025 | |
| Allergan, INC. | $95.31 | 2021-2022 | |
| Mimedx Group, INC. | $85.80 | 2025 | |
| Pfizer INC. | $61.83 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $59.49 | 2023-2025 | Zoryve |
| Incyte Corporation | $52.08 | 2023 | Opzelura |
| Organon LLC | $49.39 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $48.55 | 2021-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.35 | 2022-2025 | Ebglyss |
| Vyne Pharmaceuticals INC. | $35.99 | 2021 | |
| Amgen INC. | $35.28 | 2022-2023 | Otezla |
| Kci USA, INC. | $28.15 | 2021-2022 | |
| Novo Nordisk INC | $21.70 | 2021 | |
| Dermavant Sciences, INC. | $15.22 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $15.12 | 2025 | Xtrac |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.61 | 2022 | |
| Organogenesis INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.